Dose Escalation of IPI-493 in Hematologic Malignancies

NCT01193491 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
4
Enrollment
INDUSTRY
Sponsor class

Stopped Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on Retaspimycin HCL

Conditions

Interventions

Sponsor

Infinity Pharmaceuticals, Inc.